Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pathway to Peanut Tolerance
Sponsor: Chinese University of Hong Kong
Summary
While rigorous clinical trials have established peanut OIT as a promising therapy capable of inducing desensitization and even remission, its transition to routine clinical practice requires robust real-world evidence. Current management relies on strict avoidance, and the lack of reliable biomarkers to predict long-term success remains a significant barrier to the wider, more accessible application of OIT. Therefore, there is a critical need to evaluate peanut OIT in pragmatic, real-world settings. Such studies are essential to understand its effectiveness and safety beyond controlled trial conditions, to identify which patients benefit most, and to develop practical monitoring strategies. Generating this evidence is a crucial step toward making this treatment a viable and optimized option for the growing global population affected by peanut allergy.
Official title: A Pragmatic, Open-label Study of Peanut Oral Immunotherapy in Inducing Desensitisation or Remission in Children With Food Allergy Compared to Standard Care (Strict Allergen Avoidance)
Key Details
Gender
All
Age Range
2 Years - 17 Years
Study Type
INTERVENTIONAL
Enrollment
125
Start Date
2025-11-15
Completion Date
2029-12-31
Last Updated
2026-05-19
Healthy Volunteers
No
Interventions
Peanut Oral Immunotherapy (OIT)
This study uses a commercially available, standardized defatted peanut powder as its active intervention
Locations (1)
Department of Paediatrics, Prince of Wales Hospital
Hong Kong, Hong Kong